Literature DB >> 21508335

mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.

Jing Li1, Jianyu Liu, Jun Song, Xiaofu Wang, Heidi L Weiss, Courtney M Townsend, Tianyan Gao, B Mark Evers.   

Abstract

The mammalian target of rapamycin (mTOR) signaling exists in two complexes: mTORC1 and mTORC2. Neurotensin (NT), an intestinal hormone secreted by enteroendocrine (N) cells in the small bowel, has important physiological effects in the gastrointestinal tract. The human endocrine cell line BON abundantly expresses the NT gene and synthesizes and secretes NT in a manner analogous to that of N cells. Here, we demonstrate that the inhibition of mTORC1 by rapamycin (mTORC1 inhibitor), torin1 (both mTORC1 and mTORC2 inhibitor) or short hairpin RNA-mediated knockdown of mTOR, regulatory associated protein of mTOR (RAPTOR), and p70 S6 kinase (p70S6K) increased basal NT release via upregulating NT gene expression in BON cells. c-Jun activity was increased by rapamycin or torin1 or p70S6K knockdown. c-Jun overexpression dramatically increased NT promoter activity, which was blocked by PD98059, an mitogen-activated protein kinase kinase (MEK) inhibitor. Furthermore, overexpression of MEK1 or extracellular signal-regulated kinase 1 (ERK1) increased c-Jun expression and NT promoter activity. More importantly, PD98059 blocked rapamycin- or torin1-enhanced NT secretion. Consistently, rapamycin and torin1 also increased NT gene expression in Hep3B cells, a human hepatoma cell line that, similar to BON, expresses high levels of NT. Phosphorylation of c-Jun and ERK1/2 was also increased by rapamycin and torin1 in Hep3B cells. Finally, we showed activation of mTOR in BON cells treated with amino acids, high glucose, or serum and, concurrently, the attenuation of ERK1/2 and c-Jun phosphorylation and NT secretion. Together, mTORC1, as a nutrient sensor, negatively regulates NT secretion via the MEK/ERK/c-Jun signaling pathway. Our results identify a physiological link between mTORC1 and MEK/ERK signaling in controlling intestinal hormone gene expression and secretion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508335      PMCID: PMC3129828          DOI: 10.1152/ajpcell.00067.2011

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  71 in total

Review 1.  TOR-in(g) the nucleus.

Authors:  Chi Kwan Tsang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2007-01-06       Impact factor: 4.534

Review 2.  mTOR, translation initiation and cancer.

Authors:  Y Mamane; E Petroulakis; O LeBacquer; N Sonenberg
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

3.  Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin.

Authors:  G J Brunn; C C Hudson; A Sekulić; J M Williams; H Hosoi; P J Houghton; J C Lawrence; R T Abraham
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

4.  Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin.

Authors:  Xiangyu Liu; X F Steven Zheng
Journal:  Mol Biol Cell       Date:  2007-01-10       Impact factor: 4.138

5.  Cyclic adenosine 5'-monophosphate-stimulated neurotensin secretion is mediated through Rap1 downstream of both Epac and protein kinase A signaling pathways.

Authors:  Jing Li; Kathleen L O'Connor; Xiaodong Cheng; Fang C Mei; Tatsuo Uchida; Courtney M Townsend; B Mark Evers
Journal:  Mol Endocrinol       Date:  2006-10-26

6.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.

Authors:  David A Guertin; Deanna M Stevens; Carson C Thoreen; Aurora A Burds; Nada Y Kalaany; Jason Moffat; Michael Brown; Kevin J Fitzgerald; David M Sabatini
Journal:  Dev Cell       Date:  2006-12       Impact factor: 12.270

7.  Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells.

Authors:  Isabelle Briaud; Lorna M Dickson; Melissa K Lingohr; Jill F McCuaig; John C Lawrence; Christopher J Rhodes
Journal:  J Biol Chem       Date:  2004-11-09       Impact factor: 5.157

8.  DNA methylation contributes to expression of the human neurotensin/neuromedin N gene.

Authors:  Z Dong; X Wang; Q Zhao; C M Townsend; B M Evers
Journal:  Am J Physiol       Date:  1998-03

Review 9.  MAP kinase signalling pathways in cancer.

Authors:  A S Dhillon; S Hagan; O Rath; W Kolch
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 10.  Defining the role of mTOR in cancer.

Authors:  David A Guertin; David M Sabatini
Journal:  Cancer Cell       Date:  2007-07       Impact factor: 31.743

View more
  16 in total

1.  Rheb Inhibits Protein Synthesis by Activating the PERK-eIF2α Signaling Cascade.

Authors:  Richa Tyagi; Neelam Shahani; Lindsay Gorgen; Max Ferretti; William Pryor; Po Yu Chen; Supriya Swarnkar; Paul F Worley; Katrin Karbstein; Solomon H Snyder; Srinivasa Subramaniam
Journal:  Cell Rep       Date:  2015-02-07       Impact factor: 9.423

Review 2.  The transcription factor network associated with the amino acid response in mammalian cells.

Authors:  Michael S Kilberg; Mukundh Balasubramanian; Lingchen Fu; Jixiu Shan
Journal:  Adv Nutr       Date:  2012-05-01       Impact factor: 8.701

3.  Auto-activation of c-JUN gene by amino acid deprivation of hepatocellular carcinoma cells reveals a novel c-JUN-mediated signaling pathway.

Authors:  Lingchen Fu; Mukundh Balasubramanian; Jixiu Shan; Elizabeth E Dudenhausen; Michael S Kilberg
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

4.  PI3K p110α/Akt signaling negatively regulates secretion of the intestinal peptide neurotensin through interference of granule transport.

Authors:  Jing Li; Jun Song; Margaret G Cassidy; Piotr Rychahou; Marlene E Starr; Jianyu Liu; Xin Li; Garretson Epperly; Heidi L Weiss; Courtney M Townsend; Tianyan Gao; B Mark Evers
Journal:  Mol Endocrinol       Date:  2012-06-14

Review 5.  Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations.

Authors:  M Moschetta; A Reale; C Marasco; A Vacca; M R Carratù
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 6.  Targeting the mTOR signaling network for Alzheimer's disease therapy.

Authors:  Chong Wang; Jin-Tai Yu; Dan Miao; Zhong-Chen Wu; Meng-Shan Tan; Lan Tan
Journal:  Mol Neurobiol       Date:  2013-07-14       Impact factor: 5.590

7.  Neurotensin, a novel target of Wnt/β-catenin pathway, promotes growth of neuroendocrine tumor cells.

Authors:  Ji Tae Kim; Chunming Liu; Yekaterina Y Zaytseva; Heidi L Weiss; Courtney M Townsend; B Mark Evers
Journal:  Int J Cancer       Date:  2014-08-14       Impact factor: 7.396

8.  Activation of AMPK Stimulates Neurotensin Secretion in Neuroendocrine Cells.

Authors:  Jing Li; Jun Song; Heidi L Weiss; Todd Weiss; Courtney M Townsend; B Mark Evers
Journal:  Mol Endocrinol       Date:  2015-11-03

9.  Nuclear factor of activated T-cell c3 inhibition of mammalian target of rapamycin signaling through induction of regulated in development and DNA damage response 1 in human intestinal cells.

Authors:  Yuning Zhou; Qingding Wang; Zheng Guo; Heidi L Weiss; B Mark Evers
Journal:  Mol Biol Cell       Date:  2012-06-13       Impact factor: 4.138

10.  A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population.

Authors:  Ming Xu; Guoquan Tao; Meiyun Kang; Yan Gao; Haixia Zhu; Weida Gong; Meilin Wang; Dongmei Wu; Zhengdong Zhang; Qinghong Zhao
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.